Treatment & Management of Non Small Cell Lung Cancer
Overview of Lung Cancer
Newsletter Signup | Join Community | Cancer Types
Immunotherapy with Tiragolumab + Tecentriq improves survival in NSCLC - gets FDA Breakthrough Therapy Designation.
ADAURA clinical trial confirms Tagrisso delays cancer progression of EGFRm NSCLC - Receives full FDA Approval.
Liquid biopsies improve access to treatment options for many cancers and may replacing tissue tests & diagnostic imaging
KRAS a major driver of lung and other cancers gets FDA Breakthrough Status Designation for KRAS G12C mutated NSCLC.
Alcensa, Xalkori, and several other precision cancer medicines target ALK positive lung cancer and improve treatment.
Lobrena - a third generation ALK inhibitor drug with excellent CNS activity
Development of precision cancer medicines, immunotherapy, genomic testing are proceeding with great speed - Stay Current
Tarceva™ Improves Survival in Non-Small Cell Lung Cancer
I have small cell lung cancer; radiation to prevent spread to the brain has been recommended…
HER 2 + Lung Cancer Treatment? https://coloradocancerblogs…
Dana Farber and MDACC discover why anti-PD 1 immunotherapy doesnt work in some patients and…
High incidence of ROS 1 false negative tests reported by U Colorado researchers. http://www…